TARO Taro Pharmaceutical Industries
271
$42.30
$0.10
(0.24%)
| Watchers | 271 |
| 52-Wk Low | $28.10 |
| 52-Wk High | $45.76 |
| Market Cap | $1.59B |
| Volume | 17,613.00 |
| 52-Wk High | $45.76 |
| 52-Wk Low | $28.10 |
Taro to Release Full Year Results on May 20, 2024Business Wire • 4 days ago
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for year ended March 31, 2024, after the close of market on Monday, May 20, 2024. The...
Share to Feed
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today announced that leading independent proxy advisory firms Institutional Shareholder Services (ISS) and Glass Lewis & Co...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Taro Pharmaceutical Industries Ltd. (NYSE...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today announced that it has called an extraordinary general meeting of its shareholders (the Extraordinary General Meeting), to...
StockNews.com assumed coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO - Free Report) in a research report sent to investors on Wednesday morning. The firm issued a strong-buy rating...
StockNews.com started coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO - Free Report) in a research report sent to investors on Wednesday morning. The brokerage issued a strong-buy...
StockNews.com initiated coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO - Free Report) in a report released on Tuesday morning. The brokerage issued a strong-buy rating on the stock...
FNY Investment Advisers LLC purchased a new position in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO Free Report) in the fourth quarter, according to its most recent filing with...
StockNews.com initiated coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO Free Report) in a research note published on Monday morning. The brokerage issued a strong-buy rating...
Research analysts at StockNews.com assumed coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO Get Free Report) in a report issued on Monday. The brokerage set a...